We are live on ! Find out more
ACM

Altium Capital Management Portfolio holdings

AUM $42M
This Fund
S&P 500
This Quarter Est. Return
+33.27%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$273M
AUM Growth
+$22.8M
Cap. Flow
+$4.67M
Cap. Flow %
1.71%
Top 10 Hldgs %
26.58%
Holding
166
New
40
Increased
8
Reduced
21
Closed
31

Top Buys

Rank Stock Value
1
BLRX
BioLineRX
BLRX
+$5.92M
2
PLRX icon
Pliant Therapeutics
PLRX
+$4.11M
3
NSTG
NanoString Technologies, Inc.
NSTG
+$3.89M
4
RMD icon
ResMed
RMD
+$3.87M
5
BCAB icon
BioAtla
BCAB
+$3.62M

Top Sells

Rank Stock Value
1
STAA icon
STAAR Surgical
STAA
+$5.32M
2
LNTH icon
Lantheus
LNTH
+$3.48M
3
ESPR
Esperion Therapeutics
ESPR
+$3.45M
4
DXCM icon
DexCom
DXCM
+$3.28M
5
LIVN icon
LivaNova
LIVN
+$3.12M

Sector Composition

Rank Sector Weight
1 Healthcare 79.05%
2 Financials 10.08%
3 Industrials 0.61%
4 Consumer Staples 0.24%
5 Communication Services 0.21%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RMD icon
26
ResMed
RMD
$32.4B
$3.71M 1.36%
+17,000
New +$3.87M
NSTG
27
DELISTED
NanoString Technologies, Inc.
NSTG
$3.58M 1.31%
+280,000
New +$3.89M
QDEL icon
28
QuidelOrtho
QDEL
$1.11B
$3.57M 1.31%
50,000
– –
GH icon
29
Guardant Health
GH
$21.1B
$3.55M 1.3%
66,000
-39,000
-37% -$2M
MYGN icon
30
Myriad Genetics
MYGN
$304M
$3.55M 1.3%
186,000
-35,000
-16% -$803K
INGN icon
31
Inogen
INGN
$176M
$3.54M 1.3%
146,000
-10,000
-6% -$276K
AKYA
32
DELISTED
Akoya BioSciences
AKYA
$3.48M 1.28%
296,000
– –
PRCT icon
33
Procept Biorobotics
PRCT
$1.14B
$3.36M 1.23%
81,000
-17,000
-17% -$678K
EIGR
34
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$3.31M 1.21%
14,667
– –
KROS icon
35
Keros Therapeutics
KROS
$211M
$3.31M 1.21%
88,000
– –
NTRA icon
36
Natera
NTRA
$38B
$3.29M 1.21%
+75,000
New +$3.57M
ATEC icon
37
Alphatec Holdings
ATEC
$1.42B
$2.99M 1.1%
+342,000
New +$2.71M
NVRO
38
DELISTED
NEVRO CORP.
NVRO
$2.98M 1.09%
64,000
-25,000
-28% -$1.16M
LNTH icon
39
Lantheus
LNTH
$6.6B
$2.95M 1.08%
42,000
-46,000
-52% -$3.48M
SIBN icon
40
SI-BONE Inc
SIBN
$813M
$2.92M 1.07%
+167,000
New +$2.67M
VSTM icon
41
Verastem
VSTM
$519M
$2.55M 0.93%
250,000
– –
TMPM
42
DELISTED
Turmeric Acquisition Corp. Class A Ordinary Shares
TMPM
$2.54M 0.93%
254,000
– –
CTIC
43
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
$2.48M 0.91%
+427,000
New +$2.66M
RNAM
44
DELISTED
Avidity Biosciences
RNAM
$2.45M 0.9%
150,000
– –
TWST icon
45
Twist Bioscience
TWST
$6.84B
$2.4M 0.88%
+68,000
New +$2.89M
SRSA
46
DELISTED
Sarissa Capital Acquisition Corp. Class A Ordinary Shares
SRSA
$2.25M 0.82%
225,000
– –
ISEE
47
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$2.24M 0.82%
125,000
-111,000
-47% -$1.46M
KRMD icon
48
KORU Medical Systems
KRMD
$164M
$2.22M 0.81%
995,500
– –
ACLX
49
DELISTED
Arcellx
ACLX
$2.16M 0.79%
+115,000
New +$2.2M
OCUL icon
50
Ocular Therapeutix
OCUL
$1.92B
$2.15M 0.79%
517,133
-177,867
-26% -$896K
1
2
3 4 5

Similar funds

TA
TLS Advisors Miami, Florida $42.1M AUM 25.99% 1-Year Est. Return
SIM
Spark Investment Management New York $41.6M AUM 80.97% 1-Year Est. Return
VEPM
Vista Equity Partners Management San Francisco, California $42.7M AUM 16.65% 1-Year Est. Return
VI
Versor Investments New York $40.8M AUM 93.59% 1-Year Est. Return
BCM
Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return
VAM
Vazirani Asset Management New York $43.4M AUM 84.05% 1-Year Est. Return
SCM
Stadium Capital Management New Canaan, Connecticut $40.6M AUM 5.83% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return

Altium Capital Management's Q3 2022 Portfolio in Review

As of Q3 2022, Altium Capital Management held 166 positions worth $273M, up 9.1% from $250M the previous quarter. Its ten largest holdings account for 27% of the portfolio.

Altium Capital Management's Q3 2022 filing shows 40 new, 8 increased, 21 reduced and 31 closed positions. Its largest new stake was BioLineRX: 103,732 shares worth $3.84M. The largest sale was STAAR Surgical, an estimated $5.32M.

By sector, the portfolio is most concentrated in Healthcare at 79% of assets, up from 74% a quarter earlier, followed by Financials and Industrials.

  • Altium Capital Management's largest Q3 2022 buy was BioLineRX: 103,732 shares worth $3.84M.
  • Altium Capital Management added most to AngioDynamics in Q3 2022, an estimated $3.41M increase.
  • Altium Capital Management's biggest Q3 2022 reduction was Lantheus, cutting an estimated $3.48M.
  • Altium Capital Management fully exited STAAR Surgical in Q3 2022, selling an estimated $5.32M.
  • Altium Capital Management's ten largest holdings make up 27% of its $273M portfolio in Q3 2022.
  • Altium Capital Management opened 40 new positions and closed 31 in Q3 2022.
  • Altium Capital Management's portfolio value rose 9.1% quarter-over-quarter to $273M.

Based on Altium Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.